Over a period of 10 years, evaluate the safety and efficacy of alemtuzumab for CARE-MS II patientsKnowing what MS can do to people and seeing these results who wouldnҴ want to be treated with, or at least offered the option of being treated with,#Multiple Sclerosis·disorders.solutions·Nov 24, 2021Over a period of 10 years, evaluate the safety and efficacy of alemtuzumab for CARE-MS II patients